ES2601127T3 - Derivado de pirazol y su uso con fines médicos - Google Patents
Derivado de pirazol y su uso con fines médicos Download PDFInfo
- Publication number
- ES2601127T3 ES2601127T3 ES13787714.8T ES13787714T ES2601127T3 ES 2601127 T3 ES2601127 T3 ES 2601127T3 ES 13787714 T ES13787714 T ES 13787714T ES 2601127 T3 ES2601127 T3 ES 2601127T3
- Authority
- ES
- Spain
- Prior art keywords
- medical purposes
- pyrazole derivative
- glucopyranosyloxy
- dimethylpropionamide
- methylphenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003217 pyrazoles Chemical class 0.000 title 1
- LREHMKLEOJAVMQ-TXKDOCKMSA-N 2,2-dimethyl-3-[3-[3-methyl-4-[[5-propan-2-yl-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1h-pyrazol-4-yl]methyl]phenoxy]propylamino]propanamide Chemical compound C=1C=C(OCCCNCC(C)(C)C(N)=O)C=C(C)C=1CC1=C(C(C)C)NN=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LREHMKLEOJAVMQ-TXKDOCKMSA-N 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012105847 | 2012-05-07 | ||
| JP2012105847 | 2012-05-07 | ||
| PCT/JP2013/062755 WO2013168671A1 (ja) | 2012-05-07 | 2013-05-02 | ピラゾール誘導体及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2601127T3 true ES2601127T3 (es) | 2017-02-14 |
Family
ID=49550709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13787714.8T Active ES2601127T3 (es) | 2012-05-07 | 2013-05-02 | Derivado de pirazol y su uso con fines médicos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9273085B2 (OSRAM) |
| EP (1) | EP2848254B1 (OSRAM) |
| JP (2) | JP5663699B2 (OSRAM) |
| KR (1) | KR101868991B1 (OSRAM) |
| CN (1) | CN104284665B (OSRAM) |
| AU (1) | AU2013258566B2 (OSRAM) |
| BR (1) | BR112014027841B1 (OSRAM) |
| CA (1) | CA2872002C (OSRAM) |
| DK (1) | DK2848254T3 (OSRAM) |
| ES (1) | ES2601127T3 (OSRAM) |
| MX (1) | MX359988B (OSRAM) |
| PL (1) | PL2848254T3 (OSRAM) |
| PT (1) | PT2848254T (OSRAM) |
| RU (1) | RU2602739C2 (OSRAM) |
| WO (1) | WO2013168671A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101890959B1 (ko) | 2010-11-04 | 2018-08-22 | 알비레오 에이비 | 간질환 치료를 위한 ｉｂａｔ 억제제 |
| PT2848254T (pt) * | 2012-05-07 | 2016-10-05 | Kissei Pharmaceutical | Derivado de pirazol e utilização do mesmo para propósitos médicos |
| JP5807767B2 (ja) | 2013-02-04 | 2015-11-10 | 大正製薬株式会社 | 便秘症の予防又は治療薬 |
| CN106573033A (zh) * | 2014-06-25 | 2017-04-19 | Ea制药株式会社 | 固体制剂及其稳定化方法 |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| BR112020019624A8 (pt) | 2018-03-28 | 2022-03-03 | Avolynt | Método para tratar a hipoglicemia pós-prandial |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| SG11202012151XA (en) | 2018-06-20 | 2021-01-28 | Albireo Ab | Crystal modifications of odevixibat |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| MX2021008981A (es) | 2019-02-06 | 2021-09-08 | Albireo Ab | Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar. |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| JP7696898B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| CN114761080B (zh) | 2019-12-04 | 2024-07-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| EP4069360B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| ES3002777T3 (en) | 2020-08-03 | 2025-03-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| EP4255565A1 (en) | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| MX2008013583A (es) * | 2006-04-26 | 2008-10-31 | Genentech Inc | Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen. |
| BRPI0821773B8 (pt) * | 2007-12-27 | 2021-05-25 | Kissei Pharmaceutical | monossebacato cristalino de bis[3-(3-{4-[3-(beta-dglicopiranosilóxi)-5-isopropil-1h-pirazol-4-ilmetil]-3-metilfenóxi}propilamino)-2,2-dimetil-propionamida], composição farmacêutica e medicamento compreendendo o dito composto |
| EP2275430B1 (en) * | 2008-04-16 | 2012-05-16 | Kissei Pharmaceutical Co., Ltd. | Hemifumarate of a pyrazole derivative |
| TW201105336A (en) * | 2009-07-01 | 2011-02-16 | Kissei Pharmaceutical | Combined medicine of pyrazole derivative and biguanide drug |
| AR087701A1 (es) | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| PT2848254T (pt) * | 2012-05-07 | 2016-10-05 | Kissei Pharmaceutical | Derivado de pirazol e utilização do mesmo para propósitos médicos |
-
2013
- 2013-05-02 PT PT137877148T patent/PT2848254T/pt unknown
- 2013-05-02 AU AU2013258566A patent/AU2013258566B2/en active Active
- 2013-05-02 WO PCT/JP2013/062755 patent/WO2013168671A1/ja not_active Ceased
- 2013-05-02 US US14/399,093 patent/US9273085B2/en active Active
- 2013-05-02 PL PL13787714T patent/PL2848254T3/pl unknown
- 2013-05-02 BR BR112014027841-5A patent/BR112014027841B1/pt active IP Right Grant
- 2013-05-02 CN CN201380024202.3A patent/CN104284665B/zh active Active
- 2013-05-02 JP JP2014514708A patent/JP5663699B2/ja active Active
- 2013-05-02 RU RU2014149181/15A patent/RU2602739C2/ru active
- 2013-05-02 KR KR1020147033887A patent/KR101868991B1/ko active Active
- 2013-05-02 MX MX2014013696A patent/MX359988B/es active IP Right Grant
- 2013-05-02 CA CA2872002A patent/CA2872002C/en active Active
- 2013-05-02 DK DK13787714.8T patent/DK2848254T3/en active
- 2013-05-02 ES ES13787714.8T patent/ES2601127T3/es active Active
- 2013-05-02 EP EP13787714.8A patent/EP2848254B1/en active Active
-
2014
- 2014-12-04 JP JP2014245645A patent/JP6105546B2/ja active Active
-
2016
- 2016-01-14 US US14/995,489 patent/US9694027B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2848254T3 (en) | 2016-10-31 |
| HK1204773A1 (en) | 2015-12-04 |
| KR101868991B1 (ko) | 2018-06-19 |
| CN104284665A (zh) | 2015-01-14 |
| US9273085B2 (en) | 2016-03-01 |
| RU2014149181A (ru) | 2016-06-27 |
| PT2848254T (pt) | 2016-10-05 |
| BR112014027841B1 (pt) | 2022-08-09 |
| JPWO2013168671A1 (ja) | 2016-01-07 |
| CA2872002C (en) | 2019-01-15 |
| BR112014027841A8 (pt) | 2021-09-28 |
| RU2602739C2 (ru) | 2016-11-20 |
| JP5663699B2 (ja) | 2015-02-04 |
| CN104284665B (zh) | 2016-11-16 |
| WO2013168671A1 (ja) | 2013-11-14 |
| KR20150013671A (ko) | 2015-02-05 |
| JP2015083580A (ja) | 2015-04-30 |
| EP2848254A4 (en) | 2015-07-15 |
| US20150141631A1 (en) | 2015-05-21 |
| MX2014013696A (es) | 2015-02-05 |
| EP2848254B1 (en) | 2016-08-03 |
| CA2872002A1 (en) | 2013-11-14 |
| US20160129031A1 (en) | 2016-05-12 |
| PL2848254T3 (pl) | 2017-03-31 |
| AU2013258566B2 (en) | 2017-03-16 |
| MX359988B (es) | 2018-10-18 |
| US9694027B2 (en) | 2017-07-04 |
| EP2848254A1 (en) | 2015-03-18 |
| JP6105546B2 (ja) | 2017-03-29 |
| AU2013258566A1 (en) | 2014-11-27 |
| BR112014027841A2 (pt) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2601127T3 (es) | Derivado de pirazol y su uso con fines médicos | |
| ES2613674T3 (es) | Uso del organismo fúngico Pythium oligandrum | |
| ES2409069B2 (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| CY1123476T1 (el) | Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων | |
| ES2545959T3 (es) | Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| MX2016010519A (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| JP2015083580A5 (OSRAM) | ||
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| MX374944B (es) | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. | |
| CL2013000677A1 (es) | Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn. | |
| CL2013003497A1 (es) | Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio. | |
| ES2555778T3 (es) | Mejora de la biodisponibilidad de principios activos con función amidina en medicamentos | |
| AR096402A1 (es) | Medicamento de metformina y dihidroquercetina | |
| AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| EA201500513A1 (ru) | Продукт сомикронизации, включающий ацетат улипристала | |
| AR073265A1 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
| CL2012003006A1 (es) | Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer. | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| UY31768A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre | |
| ES2616035T3 (es) | Preparación para su uso en la profilaxis y el tratamiento de osteoporosis atípica | |
| JP2016538288A5 (OSRAM) | ||
| NI201000181A (es) | Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona. |